Array BioPharma Initiates Sponsorship Of The Myeloma Beacon
Published: Jun 4, 2014 1:45 pm
Array Biopharma, the company developing filanesib (ARRY-520) as a potential new treatment for multiple myeloma, today became the Myeloma Beacon’s first pharmaceutical industry sponsor.
Array’s sponsorship will help The Beacon continue expanding the news, support, and community it provides myeloma patients, caregivers, and health care professionals across the globe.
“It is both exciting and appropriate that Array is the Beacon’s first pharmaceutical industry sponsor,” noted the Beacon’s publisher, Boris Simkovich. “Exciting, because Array’s support will help The Beacon broaden the ways it serves the myeloma community. Appropriate, because Array – like The Beacon – is an innovative organization. Array’s investigational myeloma therapy, filanesib, is in an entirely new class of therapies different from existing myeloma treatments.”
“We are pleased to take the lead in our industry in supporting the important contributions The Myeloma Beacon is making to the myeloma community,” said Array’s chief executive officer, Ron Squarer. “We also look forward to developing filanesib as a potential new therapeutic option for myeloma patients, one that has shown substantial activity as a single agent and in combination with existing therapies.”
Filanesib belongs to a new class of drugs known as kinesin spindle protein (KSP) inhibitors, which work against myeloma and other types of cancer by disrupting cell division. Filanesib is being tested in two ongoing Phase 1 and two ongoing Phase 2 multiple myeloma clinical trials. A Phase 3 trial of the drug in combination with Kyprolis (carfilzomib) is expected to start this year.
The Beacon recognizes the support of sponsors such as Array by including their logos on the pages of the Beacon website. In addition, sponsor names are listed in the email news alerts the Beacon sends its news alert subscribers.
Beacon sponsors do not play any role, however, in the Beacon’s editorial process. All decisions regarding content published by The Beacon and its contributors are made by the Beacon’s editorial board, and editorial independence is considered a key part of the Beacon’s mission “to improve the treatment, care, and support available to current and future multiple myeloma patients worldwide.”
The Beacon’s editorial independence is further ensured by the fact that its sponsorships are non-exclusive. While Array is the Beacon’s first pharmaceutical industry sponsor, its support does not preclude other companies from becoming sponsors as well.
A complete, regularly updated list of all companies and other organizations that financially support the Beacon’s activities on behalf of the myeloma community can be viewed at the Beacon’s sponsors page.
- OncoPep Begins Sponsorship Of The Myeloma Beacon
- Myeloma Beacon Launches Sponsorship Program And Patient Advisory Board
- Myeloma Beacon Introduces New Service For Tracking Postings At Myeloma-Related Blogs
- Myeloma Beacon Launches New Myeloma Discussion Forums
- ASH 2013 Multiple Myeloma Gateway Now Available